Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -8.94
- Piotroski Score 3.00
- Grade Buy
- Symbol (IVA)
- Company Inventiva S.A.
- Price $1.87
- Changes Percentage (1.37%)
- Change $0.03
- Day Low $1.83
- Day High $1.92
- Year High $4.75
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 09/25/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.64
- Trailing P/E Ratio -1.34
- Forward P/E Ratio -1.34
- P/E Growth -1.34
- Net Income $-110,426,000
Income Statement
Quarterly
Annual
Latest News of IVA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
China new home prices manage tiny uptick again in September, private survey shows
BEIJING (Reuters) - Prices of new homes in China rose slightly in September, traditionally a peak season for house hunting, a private survey showed on Tuesday, extending months of feeble gain in a...
By Reuters | 1 hour ago -
MercadoLibre, Latam's Amazon.com rival, rides high with AI, loans, drones
MercadoLibre, Latin America's leading e-commerce platform, is expanding into fintech with innovative services like instant loans based on user data. The company aims to become a major financial option...
By Yahoo! Finance | 16 hours ago -
Epic Games accuses Samsung, Google of scheme to block app rivals
Epic Games accuses Google and Samsung of collusion to protect Google's Play store. Epic plans to file a lawsuit in California, alleging antitrust violations and reduced consumer choice. The company al...
By Yahoo! Finance | 18 hours ago